Therapy

Paclitaxel Active Against Kaposi's Sarcoma

Published in Cancer Weekly, August 14th, 1995

The anticancer agent paclitaxel appears to be active as a single agent against Kaposi's sarcoma, according to a report from the U.S. National Cancer Institute.

Paclitaxel has been shown to be active against carcinomas of the ovary, breast, lung and head and neck. The agent induces irreversible polymerization of microtubules and its cellular target is therefore similar to that of vinca alkaloids.

Because vinca alkaloids have been shown to have activity against Kaposi's sarcoma, researcher Robert Yarchoan and colleague investigated the use of paclitaxel against this condition in a group of AIDS patients ("Treatment of HIV-Associated Kaposi's Sarcoma...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-08-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry